levoleucovorin and Ulcer

The patient was a 73-year-old female. After curative resection for rectal cancer with uterus invasion, UFT/Leucovorin was administered orally for 16 months. Three years and six months after the initial surgery, en bloc cystourethrectomy was performed to control the bleeding caused by a local recurrence invading the bladder and ureter. Although postoperative FOL- FOX4/bevacizumab therapy was started, bevacizumab was discontinued after 4 courses of treatment because an ulcer was confirmed at the sigmoid colon with stoma. The ulcer was relieved by conservative medical treatment. In this case, we attempted to make a quick response because the site of the ulcer could be easily observed. During chemotherapy. Therefore, it is necessary to carefully observe the patient's conditions.

Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Rectal Neoplasms; Recurrence; Sigmoid Diseases; Ulcer

A case of severe oral ulceration, following administration of combination chemotherapy which included methotrexate, is reported. Topically applied folinic acid was effective in facilitating resolution of the oral lesions.

Topics: Administration, Topical; Carcinoma, Squamous Cell; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Mouth Diseases; Mouth Neoplasms; Ulcer

One hundred consecutive patients with previously untreated advanced squamous cell carcinoma of the head and neck were treated with induction combination chemotherapy followed by definitive surgery and/or radiotherapy, and were evaluated for radiotherapy related toxicity. The induction regimen consisted of cisplatin, bleomycin and methotrexate/leucovorin. Acute toxicity consisted predominantly of mucositis and weight loss, and was mild or moderate by degree in 94% of patients. Six percent of patients experienced severe or life threatening acute toxicities. Two acute toxic deaths were noted in this series, one from a combination of mucositis, weight loss and infection and one from hypoglycemia of unknown origin. Thirty-five percent of patients had radiation treatment interrupted briefly because of acute toxicity. Toxicity was greatest in patients who were nonresponders to induction chemotherapy and such may have been related to the continued presence of advanced tumor. Radiotherapy dose, surgical intervention and age did not have an impact on the presence or degree of acute toxicity. Late toxicities included: hypothyroidism in 32% of patients tested: osteoradionecrosis in 5% of patients, associated primarily with a composite resection (4 of 5 cases); and soft tissue ulcerations in 3%. Taken together, these data indicate that induction combination chemotherapy did not significantly increase the toxicity of subsequent radiotherapy with or without surgery.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Weight; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Hypothyroidism; Leucovorin; Male; Methotrexate; Mucous Membrane; Osteoradionecrosis; Pneumonia; Radiotherapy; Time Factors; Ulcer

The results of treating 59 patients with advanced carcinoma of the cervix with Adriamycin and methotrexate are given. Five combinations of the two cytotoxic drugs have been evaluated, differing only with regard to the methotrexate. One particular regimen has been shown to be effective with a relatively high remission rate coupled with a low rate of side effects.

Topics: Alopecia; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leucovorin; Leukopenia; Methotrexate; Mouth Diseases; Remission, Spontaneous; Taste Disorders; Ulcer; Uterine Cervical Neoplasms